Form 424B5 - Prospectus [Rule 424(b)(5)]
July 26 2024 - 1:21PM
Edgar (US Regulatory)
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-280796
PROSPECTUS SUPPLEMENT No. 3
(To the Prospectus and Prospectus Supplement
dated July 12, 2024)
Up to $2,190,416
Common Stock
60 Degrees Pharmaceuticals, Inc.
We have entered into an At
the Market Issuance Sales Agreement (the “Sales Agreement”) with WallachBeth Capital LLC (“WallachBeth”) relating
to shares of our common stock offered by this prospectus supplement, the accompanying amendment no. 2 (the “Amendment No. 2 to Prospectus
Supplement”) and the accompanying amendment no. 1 to the prospectus supplement dated as of July 22, 2024 (“Amendment No. 1
to Prospectus Supplement”), the prospectus supplement dated as of July 12, 2024 (“Prospectus Supplement”) and the prospectus
dated as of July 12, 2024 (“Base Prospectus”). In accordance with the terms of the Sales Agreement, we may offer and sell
shares of our common stock, par value $0.0001 per share, from time to time through WallachBeth acting as our agent (the “ATM Offering”).
Our common stock is listed
on The Nasdaq Capital Market under the symbol “SXTP.” On July 25, 2024, the last reported sale price of our common stock on
The Nasdaq Capital Market was $0.188 per share.
We are filing this prospectus
supplement to supplement and amend, as of July 26, 2024, the accompanying Amendment No. 2 to Prospectus Supplement, Amendment No. 1 to
Prospectus Supplement, Prospectus Supplement and Base Prospectus to increase the maximum aggregate gross sales price of our common stock
that may be offered, issued and sold under the Sales Agreement from and after the date hereof to $2,190,416 (the “ATM Offering Size
Increase”). Under the Prospectus Supplement, we initially registered up to $1,253,603 of our common stock and under the Amendment
No. 1 to Prospectus Supplement, we subsequently registered up to $1,774,640 of our common stock and under Amendment No. 2 to Prospectus
Supplement, we subsequently registered up to $1,890,705 of our common stock for offer and sale pursuant to the Sales Agreement. As of
the date of the filing of this prospectus supplement, we have sold a total of 7,525,879 shares of our common stock that are covered by
Amendment No. 2 to Prospectus Supplement, Amendment No. 1 to Prospectus Supplement and Prospectus Supplement pursuant to the Sales Agreement
for an aggregate gross sales price of $1,890,500.81.
The purpose of this prospectus
supplement is to update the accompanying Amendment No. 2 to Prospectus Supplement, Amendment No. 1 to Prospectus Supplement and the Prospectus
Supplement to reflect the ATM Offering Size Increase. Except as modified by this prospectus supplement, the terms of the ATM Offering
remain unchanged, and the Sales Agreement remains in full force and effect.
The aggregate market value of our outstanding common
stock held by non-affiliates is approximately $6,571,249, based on 20,211,995 shares of outstanding common stock, of which 18,721,508
shares are held by non-affiliates, and a share price of $0.351 per share, which was the closing sale price of our common stock as quoted
on The Nasdaq Capital Market on June 7, 2024. During the 12 calendar months prior to and including the date of this prospectus supplement,
we have sold securities with an aggregate market value of $1,890,500.81 pursuant to General Instruction I.B.6 of Form S-3. One-third of
our public float, calculated in accordance with General Instruction I.B.6 of Form S-3, is equal to approximately $299,915 after deducting
the aggregate market value of securities sold pursuant to General Instruction I.B.6 of Form S-3. In no event will we sell securities registered
on the registration statement of which this prospectus supplement forms a part in a public primary offering with a value exceeding more
than one-third of our public float in any 12-month period so long as our public float remains below $75 million pursuant to General Instruction
I.B.6 of Form S-3.
Our business and an investment in our common stock
involve significant risks. These risks are described under the caption “Risk Factors” beginning on pages S-22 and
18 of the accompanying Prospectus Supplement and Base Prospectus, respectively, and in the documents incorporated by reference into the
accompanying Amendment No. 2 to Prospectus Supplement, Amendment No. 1 to Prospectus Supplement, Prospectus Supplement and Base Prospectus,
as well as the risks and uncertainties described in other documents we file with the Securities and Exchange Commission (“SEC”).
Neither the SEC nor any
state securities commission has approved of anyone’s investment in these securities or determined if this prospectus supplement
or the accompanying Prospectus Supplement or Base Prospectus are truthful or complete. Any representation to the contrary is a criminal
offense.
WallachBeth Capital LLC
The date of this prospectus
supplement is July 26, 2024
60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Historical Stock Chart
From Oct 2024 to Nov 2024
60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Historical Stock Chart
From Nov 2023 to Nov 2024